<DOC>
	<DOCNO>NCT02264119</DOCNO>
	<brief_summary>Study assess absorption 20 mg Lefradafiban two formulation , physiological condition 40 mg Pantoprazole</brief_summary>
	<brief_title>Influence Pantoprazole Pharmacokinetics Fradafiban After Multiple Oral Doses Lefradafiban Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>Healthy male subject determine result screen Signed write informed consent accordance good clinical practice ( GCP ) local legislation Age ≥ 18 ≤ 60 year , plan stratification : age &lt; 40 year ( 4 subject ) ≥ 40 year ( 8 subject ) Broca ≥ 20 % ≤ + 20 % Use drug might influence result trial within 10 day prior administration trial Intake drug long halflife ( &gt; 24 hour ) within 1 month prior administration Participation another trial investigational drug within 2 month prior administration trial Drug abuse Alcohol abuse ( &gt; 60 g/day ) Smoker ( &gt; 10 cigarette 3 cigar 3 pipes/day ) inability refrain smoke study day Excessive physical activity within 5 day prior administration trial Blood donation within 1 month prior administration trial History current gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological , hormonal disorder Chronic relevant acute infection Diseases central nervous system ( epilepsy ) psychiatric disorder History Allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Any bleeding disorder include prolonged habitual bleeding Other hematologic disease Cerebral bleeding ( e.g . car accident ) Recent surgical procedure Thrombocytes &lt; 150000/µ Any find medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance Any laboratory value outside clinically accept reference range Other disease abnormality clinical relevance</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>